Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

CONTEXT: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. OBJECTIVE: Our objective was to demonstrate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2014
Materias:
Endocrine Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965714/
https://www.ncbi.nlm.nih.gov/pubmed/24423324
http://dx.doi.org/10.1210/jc.2013-2480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965714/
https://www.ncbi.nlm.nih.gov/pubmed/24423324
http://dx.doi.org/10.1210/jc.2013-2480

Ejemplares similares